An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Sierra Oncology to Present at Three September Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
SAN MATEO, Calif.--(BUSINESS WIRE)--
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology will provide a company update at the HC Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit. He will participate in a fireside chat discussion at the 2021 Cantor Virtual Global Healthcare Conference.
Presentation Details:
Conference:
HC Wainwright 23rd Annual Global Investment Conference
Date:
Monday, September 13, 2021
Time:
On demand viewing beginning at 7:00 am ET
Conference:
Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Date:
Tuesday, September 21, 2021
Time:
Presentation beginning at 2:05 pm ET
Conference:
2021 Cantor Virtual Global Healthcare Conference
Date:
Tuesday, September 28, 2021
Time:
Fireside chat beginning at 4:00 pm ET
All three presentations will be webcast and available at the times noted above on the Investors section of Sierra’s corporate website in the Events & Webcast tab.
About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
